Introduction
Vascular endothelial growth factor (VEGF) is a potent angiogenic agent having tumor-promoting activity. Tumor cells secrete VEGF that increases the proliferation of endothelial cells leading to tumor angiogenesis and subsequent tumor progression (Ferrara et al., 2003) . In addition to its effects on endothelial cells, VEGF may also act directly on tumor cells in an autocrine manner to increase survival and proliferation (Fukumura et al., 1998; Dias et al., 2000; Bellamy et al., 2001; Soker et al., 2001; Strizzi et al., 2001; Bates et al., 2003; Qi et al., 2003; Mercurio et al., 2004; Steiner et al., 2004) . We have shown that VEGF binds to its cognate receptor VEGFR-1 (Flt1 also known as fms-like tyrosine kinase-1) in neuroblastoma and rhabdomyosarcoma leading to activation of mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinase-1,2 (ERK1,2) and subsequent tumor cell survival Gee et al., 2005) . During hypoxia-induced stress, increased expression of Flt1 rescued the tumor cells from hypoxia-induced cell death . Our preliminary data suggested that exposure to cisplatin (cis-diammine-dichloroplatinum (II); CDDP) may increase Flt1 expression in osteosarcoma cell lines (Das B et al.) . The role of VEGF autocrine signaling during oxidative stress. 7th International Symposium on Cytokines and Chemokines; 8-9 September 2005; World Congress of Gastroenterology, Montreal, Canada). Therefore, we speculated that in the fraction of tumor cells resistant to chemotherapy, treatment-induced Flt1 autocrine signaling may provide survival signaling. Recently, a tumor side-population (SP) fraction has been isolated from tumors exhibiting high resistance to chemotherapeutic treatment (Patrawala et al., 2005) . Therefore, we studied the potential upregulation of Flt1 in the SP fraction and subsequent tumorigenicity.
Chemotherapeutic agents have multiple effects on tumor cells including transient modulation of growth factor signaling, drug efflux pumps and detoxification systems leading to tumor cell survival (Cara and Tannock, 2001; Cole and Tannock, 2004; Kim and Tannock, 2005) . Recently, Biswas et al. (2007) showed that chemotherapeutic agents like doxorubicin may increase transforming growth factor-b signaling leading to survival and expansion of highly tumorigenic cells. Chemotherapeutic agents may transform non-tumorigenic into tumorigenic tumor cells. For example, an osteosarcoma cell line HOS, which is non-tumorigenic became tumorigenic following acute exposure to heavy metals including platinum (Lin and Costa, 1994; Miller et al., 1998 Miller et al., , 2001 Salnikow et al., 1999) . Cisplatin, a platinum drug, has been shown to activate MAPK/ ERK1,2 growth signaling pathway leading to either tumor cell survival or death depending upon the cell types (Woessmann et al., 2002; Brozovic and Osmak, 2007) . Our unpublished study suggested that cisplatin treatment may activate the VEGF/Flt1 autocrine signaling pathway in tumor cell lines including HOS (Das B, Tsuchida R, Yeger H, Malkin D and Baruchel S) . The role of VEGF autocrine signaling during oxidative stress. 7th International Symposium on Cytokines and Chemokines; 8-9 September 2005; World Congress of Gastroenterology, Montreal, Canada).
Thus, chemotherapeutic drugs may induce cellular signaling pathways involved in tumor growth and progression leading to tumorigenicity and/or repopulation. Understanding the molecular mechanism involved in these processes may help to develop new combination therapy regimens to reduce the incidence of tumor relapse. Therefore, we investigated the potential role of VEGF/ Flt1 autocrine signaling in a CDDP model of druginduced tumorigenicity. We found that CDDP treatment activates VEGF/Flt1 autocrine signaling in the highly tumorigenic SP fraction of cell lines obtained from osteosarcoma, rhabdomyosarcoma and neuroblastoma. Subsequently, we show that the CDDP-induced SP fraction and its tumorigenic potential can be reduced by inhibiting VEGF/Flt1 autocrine signaling. Furthermore, we found that several stemness genes, including Nanog, are highly expressed in the CDDP-treated SP fraction both in vitro and in vivo. Our findings highlight the importance of VEGF/Flt1 autocrine signaling in drug-induced tumorigenicity including the expansion of an SP fraction expressing self-renewal genes including Nanog and Oct-4.
Results

CDDP treatment increases tumorigenic potential of osteosarcoma HOS cells
We used a human osteosarcoma cell line, HOS, as a model to study the role of VEGF/Flt1 autocrine signaling in CDDP-induced tumorigenicity. This cell line is non-tumorigenic when injected into nude mice (McAllister et al., 1971) , and becomes tumorigenic following exposure to heavy metals (Lin and Costa, 1994; Miller et al., 2001; Miura et al., 2005) . We found that exposure of HOS cells to cisplatin (CDDP) (2 mM Â 3 days) increased in vitro tumorigenicity (Figures 1a and b) as measured by in vitro matrigel assay (Miller et al., 2001) , and induced formation of large tumors when injected into nude mice (2 Â 10 6 cells per injection, n ¼ 16; Figures 1c and d) .We observed that the untreated HOS group (10 Â 10 6 cells per injection) reached 0.05 cm 3 size (four out of eight injection; Figure 1c ). Histopathological examination of tumors at 50 days revealed that the area of inoculation was filled with fibroblasts and a few scattered tumor cells, whereas the CDDP-treated tumors showed tumor cells with surrounding blood vessels (Figure 1d ). Considering that neovascularization is involved in the progression of tumor from dormancy to a state of rapid growth (Folkman, 1971) , we measured the MVD (microvessel density) of the 0.05 cm 3 growth using CD34 staining (Gasparini and Harris, 1995) and found that CDDPtreated xenograft showed numerous CD34 staining microvessels, whereas untreated growth did not show evidence of angiogenesis (Supplementary Figure 1) .
We then investigated the potential role for SP cells in CDDP-treated HOS cell tumorigenicity. In all the following assays, 3-day exposure to 2 mM CDDP was used as a standard treatment for in vitro as well as in vivo studies.
CDDP-treated HOS SP fraction (SP cddp ) is highly tumorigenic Tumor SP cells characterized by high expression of drug efflux pumps such as BCRP1 and MDR1 have been found to contain the tumor stem cell fraction (Hirschmann-Jax et al., 2004; Kondo et al., 2004; Patrawala et al., 2005) . We show that the HOS cell line contains a small fraction of SP cells, which can be maintained in serum-free media containing growth factors bFGF (basic fibroblast growth factor) and PDGF (platelet-derived growth factor; Supplementary Figure 2A ). Figure 2a shows that CDDP treatment increases the SP cell fraction significantly.
We then sorted SP, non-SP, SP cddp (SP cells obtained following 3 days treatment of HOS cells with 2 mM CDDP) and non-SP cddp (non-SP cells obtained following 3 days treatment of HOS cells with 2 mM CDDP) and investigated the expression of the stemness-associated genes Nanog and Bmi-1 by quantitative reverse transcriptase (RT)-PCR (qPCR). Both these genes are highly expressed in the SP cddp fraction (Figure 2b) . Furthermore, colony assay showed increased clonogenic efficiency of CDDP-treated SP fraction (SP cddp ) compared with the untreated SP and treated non-SP (non-SP cddp ) fractions (Figure 2c ). In addition, when SP cddp cells were injected into nude mice, they formed rapidly growing tumors (Figure 2d ) compared with the SP and non-SP cddp group. Furthermore, the SP cddp xenograft showed a 1.5-fold increase in MVD compared with CDDP-treated unsorted HOS cell-derived xenografts (Mann-Whitney test; Supplementary Figure 1) . siRNA/Flt1 knockdown reduces HOS SP cddp fraction and subsequent tumorigenicity Previously, we reported that VEGF/Flt1 autocrine signaling is involved in the survival of tumor cells during hypoxia as well as drug exposure . Here, we first show that HOS cells express functionally active Flt1 (VEGFR1) (Figures 3a and b) , but not KDR (kinase insert domain-containing receptor, VEGF receptor-2) (data not shown). Small interfering RNA (siRNA)/Flt1 knockdown completely inhibited recombinant human VEGF (rhVEGF)-mediated MAPK/ERK1,2 activity (Figure 3b ), suggesting that VEGF/Flt1 autocrine signaling is mediated via the mitogenic MAPK/ERK1,2 signaling pathway. This result is consistent with previous findings on VEGF/Flt1 autocrine signaling Gee et al., 2005) . We then investigated the potential role of VEGF/Flt1 signaling in the CDDP-induced SP fraction, and found that siRNA/Flt1 knockdown reduced the SP cddp fraction significantly, with associated reduction in Nanog and Bmi-1 expression (Figure 3c and d) . Furthermore, when siRNA-treated cells were injected into nude mice, CDDP-mediated tumorigenicity was significantly reduced (Figure 4 ). Xenograft tissues derived from the CDDP þ siRNA/Flt1-treated group showed a marked increase in necrotic cores and caspase-3-positive apoptotic cells (Figure 4b ) compared with the CDDP-treated group. Most importantly, when tumor tissues were dissociated and the SP fraction sorted out, post-CDDP-treated xenografts contained a higher fraction of SP cells compared with the combination treatment (CDDP þ siRNA/Flt1)-derived xenografts (P ¼ 0.013; Figure 4c ). qPCR analysis of the SP fraction showed significant reduction of Nanog expression in the siRNA/Flt1-treated group. Immunohistochemical labeling revealed a significant reduction in Nanogexpressing cells in the siRNA/Flt1 knockdown group (Figure 4d ). These results further suggest that the SP cddp fraction plays an important role in HOS cell tumor growth and angiogenesis. siRNA/Flt1 knockdown reduces this tumorigenic fraction ( Figure 3c ) leading to decreased tumor growth (Figure 4a ). , where a few tumor cells were seen among numerous fibroblasts ( Â 400). Detailed results are given in Figure 2c and the associated table in the figure.
CDDP treatment upregulates VEGF and Flt1 expression R Tsuchida et al
Interestingly, we noted that the control group (10 Â 10 6 cells injected) showed progressive growth until it reached 0.05 cm 3 but failed to 'take off' (Figure 4a ). The injection of a large number of cells and the accumulation of fibroblasts ( Figure 1d ) may have allowed progressive growth for 50 days after inoculation. Failure to take off may be due to the lack of tumorigenic SP cddp cells and angiogenesis. MVD study suggests that SP cddp -derived tumor xenograft is vascular, whereas untreated dormant growth (0.05 cm described the VEGF/Flt1 autocrine loop in these two cell lines and showed that treatment with anti-Flt1 antibody (10-20 mg ml À1 ) completely reduces VEGF/Flt1 autocrine signaling in SK-N-BE(2) and RH-4 cells . These two cell lines contain a small fraction of SP cells (Supplementary Figure 2A) and are highly resistant to CDDP treatment (Supplementary Figure 2B ). Injection of 2.5 Â 10 5 SP cells formed rapidly progressing tumors (four tumors developed out of four injections for each cell type), whereas a similar number of non-SP (six injections for each cell type) cells failed to form tumors (data not shown). When these cell lines were exposed to CDDP, the SP fraction increased significantly and could then be reduced by anti-Flt1 antibody treatment (Figure 5a ). We found that clonogenic activity and stemness gene expression of SP cddp was significantly enhanced (Figures 5b and c) , which was completely downregulated following treatment with anti-Flt1 antibody.
CDDP treatment induces VEGF/Flt1 autocrine signaling in the SP cddp fraction: role of MAPK/ERK1,2 signaling Recently, Biswas et al. (2007) demonstrated that chemotherapeutic agents like doxorubicin may increase transforming growth factor-b signaling leading to survival and expansion of highly tumorigenic cells. Here, we found that CDDP treatment increases the SP fraction, which can be reduced by inhibiting VEGF/Flt1 autocrine signaling. Hence, it can be hypothesized that CDDP treatment may have increased VEGF and Flt1 expression in the SP fraction leading to the survival and expansion of the SP cddp fraction. Here, we first investigated the potential CDDP-induced upregulation of VEGF and Flt1 signaling in HOS cells. We found that CDDP treatment upregulates the expression of both Flt1 and VEGF expression in the HOS SP fraction (Figures 6a and c) and SK-N-BE(2)/RH-4 (Figures 7a-c) . We did not observe significant upregulation of KDR and neuropilin-1 (data not shown).
When VEGF secretion was measured in HOS SP, SP cddp and non-SP cddp (CDDP-treated non-SP cells), the SP cddp cells showed significantly higher levels of secretion compared with the SP and non-SP cddp fractions (Po0.05; Supplementary Figure 2C) . Interestingly, the secretion of VEGF in HOS non-SP cddp also increased significantly (Po0.05; Supplementary Figure 2C) . qPCR study further revealed that the expression of VEGF increased in the non-SP cddp fraction, even though the level of expression was significantly lower than the SP cddp fraction in all the cell lines (Figures 6c and 7b) . These results indicate that there was a specific increase of Flt1 in SP cddp fraction, whereas VEGF expression was increased in both SP and non-SP fraction; however, VEGF expression was higher in the SP cddp compared with the non-SP cddp fractions.
Recently, we found that sustained activation of MAPK/ERK1,2 upregulates VEGF/Flt1 signaling in SK-N-BE(2) . Since CDDP treatment may activate MAPK/ERK1,2 signaling (Woessmann et al., 2002; Brozovic and Osmak, 2007) , we examined the effect of CDDP treatment on the level of phosphorylated forms of MAPK/ERK1,2 and found that the latter is markedly increased following CDDP treatment (Figure 6b ). We then investigated the effect of U0126, a specific inhibitor of MAPK/ERK1,2 on the expression of VEGF and Flt1 following CDDP treatment. We used a dose of 20 mM U0126, which downregulates rhVEGF-mediated MAPK/ERK1,2 in HOS as well as RH-4 and SK-N-BE(2) . We found that U0126 treatment reduced CDDPinduced VEGF and Flt1 expression in HOS (Figure 6c ) and RH-4/SK-N-BE(2) (Figures 7a-c) . Immunofluorescence studies showed that phospho-ERK1,2 level was increased in both SP cddp and non-SP cddp compared with SP cells. However, Flt1 expression was mainly increased in the SP cddp fraction (Figure 6d ). U0126 treatment reduced Flt1 expression in the SP fraction (Figure 6c ) and reduced CDDP-induced SP cddp fraction significantly in HOS (data not shown) as well as SK-N-BE(2) (Figure 7d ). 
Discussion
Vascular endothelial growth factor/Flt1 autocrine signaling plays an important role in the survival of drugresistant tumor cells Gee et al., 2005) . Environmental stress such as hypoxia upregulates VEGF/Flt1 signaling in the tumor cells leading to enhanced tumorigenic potential including angiogenic potential . Here, we investigated the role of chemotherapeutic-induced stress in the upregulation of VEGF/Flt1 autocrine signaling and subsequent tumorigenic potential in several tumor cell lines. We particularly investigated the role of CDDP, a commonly used chemotherapeutic agent in the upregulation of VEGF/Flt1 autocrine signaling in tumor SP fraction. We found that (1) CDDP treatment increases the SP fraction of three different cell lines; (2) CDDP treatment increases VEGF and Flt1 expression in the SP fraction by activating MAPK/ERK1,2 signaling; and (3) inhibition of Flt1 reduces the tumorigenic fraction.
Recently, tumor SP fractions have been shown to contain tumorigenic cells in many tumor types. The SP fraction is highly tumorigenic, drug-resistant and expresses 'stemness' genes such as Nanog, Oct-4 and Bmi-1 Hirschmann-Jax et al., 2005; Patrawala et al., 2005 Patrawala et al., , 2007 Ho et al., 2007) . It has been shown that less than 1000 SP cells are sufficient to form rapidly progressing xenografts (Ho et al., 2007; Patrawala et al., 2007) . However, here we found that not all SP cells are tumorigenic since 1 Â 10 5 -0.5 Â 10 6 SP cells were required to obtain SK-N-BE(2) and RH-4 xenografts. The HOS cell line contains a 2-3% fraction of SP cells, even though it is non-tumorigenic. CDDPtreatment increased the tumorigenic capacity including the expression of Nanog in the HOS SP cddp fraction both in vitro and in vivo. For the first time, we have demonstrated that drug exposure may actually enhance the tumorigenic potential of the SP fraction. We found that CDDP treatment led to a significant increase in the SP fraction including specific upregulation of Flt1 and stemness gene expression in the SP fraction. In our experimental model, cells were first treated with CDDP, and then SP and non-SP fractions were sorted and qPCR analysis of Flt1 expression was performed. Hence, it can be argued that an apparent increase of Flt1/stemness gene expression in the SP fraction may be due to either survival (selection) and/or expansion (induction) of SP cells having Flt1/stemness gene expression. While selection may explain the increase of Flt1/stemness gene expressing HOS SP cddp cells, the RH-4 and SK-N-BE(2) are highly resistant to CDDP treatment (Supplementary Figure 1B) , and therefore, apparent selection of Flt1-expressing SP cddp cells is unlikely. Instead, CDDP-mediated stress may expand SP cddp fraction. We found that hypoxia-induced oxidative stress expands highly tumorigenic SP cells (Das et al., 2007) (Das B . The role of VEGF autocrine signaling in hypoxia and oxidative stress driven 'stemness switch': implications in solid tumor progression and metastasis. PhD thesis, Institute of Medical Sciences, University of Toronto, Canada). Earlier, it was reported that chemotherapy-induced stress led to the expansion of normal bone marrow stem cells (Richman et al., 1976; Cottler-Fox et al., 2003) . Hence, CDDP-induced expansion of a highly tumorigenic SP cddp fraction is a likely possibility. Such a stress-induced expansion of tumorigenic cells would involve autocrine signaling pathways such as VEGF/Flt1 signaling. Our findings that siRNA/ Flt1 inhibition significantly decreased the SP cddp fraction support this possibility. It is possible that only tumorigenic SP cells are capable of activating the signaling pathway leading to expansion, which would explain why the Flt1/stemness gene expression did not change in the non-tumorigenic non-SP cddp fraction.
Overall, our findings in HOS, SK-N-BE(2) and RH-4 cells suggest that CDDP-induced SP fraction propagation is mediated by upregulation of VEGF and its receptor Flt1. VEGF/Flt1 autocrine signaling is mediated by MAPK/ERK1,2 signaling, the latter being found to be upregulated during stress including following CDDP treatment (Woessmann et al., 2002; Brozovic and Osmak, 2007) . Numerous studies have reported the activation of the MAPK superfamily including ERK1,2 in tumor cells following stress (Brozovic and Osmak, 2007) . The activation of these signaling pathways may be involved in cell survival as well as cell death depending upon the specific stimulus and cell type involved. We found that ERK1,2 activation following hypoxia reperfusion injury leads to cell survival in neuroblastoma cell lines . On the other hand, hypoxia reperfusion-activated MAPK/ERK1,2 in cardiac tissue may lead to protection as well as damage to cardiac tissue depending on the degree of stimulation and cell type involved (Behrends et al., 2000) . Ranganathan et al. (2006) reported that upregulation of MAPK/ERK1,2 signaling may activate dormant tumor cells leading to the expansion of tumorigenic cells and subsequent tumor progression. However, no molecular mechanism was identified that accounted for the activation of the dormant tumors. Here, our findings on MAPK/ERK1,2-mediated activation of VEGF/Flt1 signaling in the SP fraction suggest a molecular mechanism by which the mitogenic signaling of MAPK/ERK1,2 may activate dormant tumor stem cell-like SP cells. In the clinical setting, it may be necessary to first assess the effect of CDDP on the specific tumor cell type to determine whether the drug induces VEGF and MAPK/ERK1,2 signaling activity. If it does, combination therapy might be considered beneficial. Therefore, use of such preclinical data may help to design effective and innovative combination therapies.
Our findings on the CDDP-induced activation of VEGF/Flt1 signaling in a subset of tumor SP cells warrant further investigation including whether other chemotherapeutic agents may have similar effect. Our preliminary investigation suggests that doxorubicin and methotrexate may also increase SP fraction and Flt1 expression in the tumor cells ( Supplementary  Figures 3A and B) .
In summary, we report on a novel mechanism of CDDP-induced tumorigenicity and demonstrate that even brief exposure of tumor cells to drugs may lead to the upregulation of VEGF autocrine signaling. One of the important and direct implications of our result is that primary dormant tumors may become highly tumorigenic following exposure to drugs by activating a signaling loop between MAPK/ERK1,2 and VEGF/ Flt1. Hence, combination therapies that include either anti-Flt1 or MAPK/ERK1,2 inhibitors have the potential benefit to reduce the incidence of drug-induced tumor cell repopulation and relapse.
Methods
Cell lines and culture
The human osteosarcoma cell line HOS and neuroblastoma cell line SK-N-BE(2) were obtained from the American Tissue Culture Collection (ATCC, Rockville, MD, USA). The RH-4 rhabdomyosarcoma cell line was kindly provided by Dr Thomas Look (Dana-Farber Cancer Institute, Boston, MA, USA). All cell lines were maintained in the culture media as recommended by ATCC.
Reagents and drugs
Cisplatin (CDDP), doxorubicin and methotrexate were obtained from Sigma (St Louis, MO, USA). Recombinant human VEGF 165 (rhVEGF 165 ), nonspecific goat IgG and a neutralizing antibody against VEGF 165 (anti-human mouse monoclonal antibody) were purchased from R&D Systems (Minneapolis, MN, USA). Source of other reagents, antibodies and kits are noted with assay descriptions.
Side-population analysis
The protocol was based on that described by Montanaro et al. (2004) . Details are given in the Supplementary Methods section.
Western blot analysis and immunoprecipitation
The overall method has been previously described in detail . Details are given in the Supplementary Methods section.
Methylcellulose-based clonogenic assay
The assay was performed as previously described (Das et al., 2003) . Tumor cells were washed three times with phosphatebuffered saline and then 2 Â 10 3 cells were plated in methylcellulose media (Stem Cell Inc., Vancouver, BC, USA), and colonies were counted after 2 weeks using an inverted microscope.
Reverse transcriptase-PCR Details are given in the Supplementary Methods section.
Real-time quantitative RT-PCR Real-time qPCR was performed using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA). Details are provided in the Supplementary Methods section.
Small interfering RNA Small interfering RNA knockdown of genes was performed according manufacturer's instructions (details are provided in the Supplementary Methods section).
ELISA analysis
The measurements of both VEGF were carried out using an ELISA kit (R&D Systems) according to the manufacturer's protocols. Samples consisted of conditioned media harvested after treatment with or without CDDP (2 mM) for 3 days in serum-free media. Fluorescence activity was converted to actual concentration by a standard curve and normalized by cell number.
Immunofluorescence and immunohistochemistry
Standard protocol was used as described in the Supplementary Methods section.
In vitro matrigel tumorigenicity assay Tumor cells were incubated for 8 h on top of a matrigel layer. Cells with tumorigenic potential form branched networks of cells that grow and invade the matrigel structures, whereas non-tumorigenic cells either form colonies or undergo cell death (Miller et al., 2001) . We modified the assay, where cells were treated with serum-free medium containing 200 ng ml À1 SDF1a (stromal cell-derived factor-1a), and then plated in growth factor-free matrigel (BD Bioscience, San Jose, CA, USA).
In vivo tumorigenicity assay Tumorigenicity of the HOS cells was measured by tumor incidence (number of tumors/number of injection of 2-10 Â 10 6 cells), and latency was measured as time required to form palpable tumors of more than 0.05 cm 3 . Details are given in the Supplementary Methods section.
Statistical analysis
The data are presented as mean ± s.d. The statistical calculations were performed with GraphPad Prism 4.0 (Hearne Scientific Software, Chicago, IL, USA) using Student's t-test for cell survival assays. A value of Pp0.05 was considered statistically significant.
